Biotech

All Articles

8 months after a $213M fundraise, gene editor Tome helps make reduces

.After bring up $213 thousand in 2023-- among the year's biggest private biotech rounds-- Tome Biosc...

BioMarin creates director staff with biotech vets-- Chutes &amp Ladders

.Invite to recently's Chutes &amp Ladders, our summary of notable management hirings, firings as wel...

Biopharma Q2 VC reached highest level since '22, while M&ampA decreased

.Equity capital funding right into biopharma cheered $9.2 billion across 215 sell the 2nd fourth of ...

Bicara, Zenas seek IPOs to press late-phase resources toward market

.Bicara Therapies and Zenas Biopharma have provided fresh motivation to the IPO market along with fi...

Genentech to finalize cancer cells immunology study department

.Genentech is going to close its own cancer cells immunology research study team, as well as unit mi...

Kezar goes down strong lump yet to confirm its own well worth in period 1 test

.Kezar Life Sciences is actually dropping its own dim phase 1 sound lump medication as the biotech g...

Acelyrin drops izokibep, drops 3rd of staff

.In spite of izokibep keeping its newly found winning touch in the medical clinic, Acelyrin is no mo...

Rivus' stage 2 obesity-related cardiac arrest test attacks endpoint

.Rivus Pharmaceuticals has plumped up the leads of its own fat-busting, muscle-sparing medicine cand...

Ovid halts preclinical job, IV program after soticlestat neglect

.Ovid Therapy currently uncovered last month that it was trimming back its headcount as the company ...

Eli Lilly opens up $700M nucleic acid R&ampD center in Boston ma Seaport

.Eli Lilly has actually opened up a $700 thousand R&ampD facility in the Boston ma Seaport, boosting...